Dr. Singh on Research With Antibody-Drug Conjugates in Advanced Bladder Cancer

Parminder Singh, MD
Published: Wednesday, Sep 04, 2019



Parminder Singh, MD, hematologist/oncologist, Mayo Clinic, discusses research being done with antibody-drug conjugates (ADCs) in advanced bladder cancer.

The majority of patients who receive a checkpoint inhibitor will progress, says Singh. In general, the response rate among all checkpoint inhibitors is approximately 15% to 20%. This has left a large unmet need and has prompted research with ADCs, such as enfortumab vedotin and sacituzumab govitecan, adds Singh. There are several ongoing trials with these agents.

Data with enfortumab vedotin, which were presented at the 2019 ASCO Annual Meeting, showed a significant response rate of approximately 44% in patients who had received prior immunotherapy and chemotherapy. Up to 12% of patients achieved a complete response, which is very promising among a pretreated patient population. Singh anticipates that the agent will move forward and become a definitive therapeutic option for this patient population. In July 2019, a biologics license application was submitted to the FDA for the agent for patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1/PD-L1 inhibitor and platinum-based chemotherapy.
SELECTED
LANGUAGE


Parminder Singh, MD, hematologist/oncologist, Mayo Clinic, discusses research being done with antibody-drug conjugates (ADCs) in advanced bladder cancer.

The majority of patients who receive a checkpoint inhibitor will progress, says Singh. In general, the response rate among all checkpoint inhibitors is approximately 15% to 20%. This has left a large unmet need and has prompted research with ADCs, such as enfortumab vedotin and sacituzumab govitecan, adds Singh. There are several ongoing trials with these agents.

Data with enfortumab vedotin, which were presented at the 2019 ASCO Annual Meeting, showed a significant response rate of approximately 44% in patients who had received prior immunotherapy and chemotherapy. Up to 12% of patients achieved a complete response, which is very promising among a pretreated patient population. Singh anticipates that the agent will move forward and become a definitive therapeutic option for this patient population. In July 2019, a biologics license application was submitted to the FDA for the agent for patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1/PD-L1 inhibitor and platinum-based chemotherapy.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x